ESTRO 36 _______________________________________________________________________________________________ antagonizing SET could enhance the effects of RT against HCC. Using sub-G1 analysis, we showed that adding EMQA significantly increased RT-induced apoptosis of HCC cells. The number of tumor colony was also significantly decreased in HCC cells exposing to EMQA plus RT than either of the treatment alone. Lastly, using the PLC5 xenografted tumor model, the synergistic effects of SET antagonist combining RT were also observed. Conclusion SET is a novel oncoprotein that affects the radiosensitivity of HCC cells. A combination therapy with RT and the SET antagonist, such as EMQA, enhanced RTinduced apoptosis of HCC cells in vitro and in vivo.
Purpose or Objective
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a cumulative 5-year overall survival of less than 5% for all stages. Thirty percent of patients diagnosed with pancreatic adenocarcinoma present with a locally advanced disease and could benefit from chemoradiotherapy with gemcitabine, which is effective but toxic. Over the past few years, studies have focused on the development of targeted radiosensitizer such as poly(ADP-ribose) polymerase (PARP) inhibitor. We conducted this in vitro study to determine whether PARP inhibition enhances radiation-induced cytotoxicity of pancreatic adenocarcinoma.
Material and Methods
Pancreatic carcinoma cells, MIA PaCa-2 (BRCA1/2 wildtype) , were treated with olaparib and/or gemcitabine and/or irradiation (2,5 and 10 Gy). In vitro cell viability, clonogenic assay, cell cycle distribution, γ-H2AX quantification, apoptosis and autophagy were assessed.
Results
In vitro, treatment with olaparib alone at 1 µM was not cytotoxic but highly radiosensitized cells (standard enhancement ratio =1.23+/-0.02) and particularly at high dose per fraction (10 Gy). After 24 hours, the number of remaining γ-H2AX stained cells was higher when cells were treated with a combination of 10 Gy irradiation and olaparib compared to irradiation or olaparib alone. Furthermore, combination of olaparib and irradiation induced a G2/M arrest. In contrast, a non-cytotoxic concentration of gemcitabine could also radiosensitize cells, but clearly less than olaparib (SER=1.11+/-0.04). Radiosenzitization by gemcitabine was associated with percentage of cells blocked in early S-phase just before irradiation. Finally, cell death quantification after 24 hours showed that none of the treatments induced apoptosis, whereas gemcitabine or 10 Gy irradiation alone induced autophagy.
Conclusion
Our results showed that MIA PaCa-2 cells could be radio sensitized with low dose of olaparib , through an increase of unrepaired double-strand breaks and a block in G2 phase. The radiosensitization was higher with high dose radiation. This may be translated into an enhancement of local control in vivo and better disease free survival. Investigations in three other pancreatic cells lines are in progress. analysis to obtain information on intravascular diffusion, related to perfusion (F: perfusion factor) and subsequently tumor vessels perfusion.
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Results
With the MDA-MB 231, we observed a significant peak of F at day 6 after irradiation, this increasing is about 60% of the basal value (n=6, p<0,05). Moreover, D* parameters (also related to perfusion) increase at the same time. The other parameters of the DW-MRI, ADC and D presented no modification. We observed similar results with 4T1 cells, where F increased at day 3 (about 55%, n=10, p<0,05) then returned to initial level. The difference in timing for the peak of F (day 6 vs day 3) could be related to the difference in tumor growth according to the cell line (four weeks for MDA-MB 231 cells vs one week for 4T1cells). We performed surgery at the time of the F parameter peak in the MDA-MB 231 and we observed a decrease of the metastasic burden compared to surgery performed at day 4 or day 11(absolute number of metastasis 23 VS 1 VS 8 with n=4).
Conclusion
For the first time, we demonstrate the feasibility of repetitive fMRI imaging in preclinical models after NeoRT.
With these models, we show a significant difference in perfusion-related parameters (D* and F) at a specific time point depending of the tumor cells. 
